Role of ubiquitin-specific peptidase 22 in carcinogenesis of human pharyngeal squamous cell carcinoma

Dou,Yunling; Lin,Jiaping; Shu,Haihua; Jiang,Nan

doi:10.3892/mmr.2014.2589

Role of ubiquitin-specific peptidase 22 in carcinogenesis of human pharyngeal squamous cell carcinoma

Authors:
- Yunling Dou
- Jiaping Lin
- Haihua Shu
- Nan Jiang
View Affiliations

Affiliations: Department of Anesthesiology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong 510080, P.R. China, Department of Neurosurgery, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong 510080, P.R. China
Published online on: September 22, 2014 https://doi.org/10.3892/mmr.2014.2589
Pages: 2973-2978

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Human pharyngeal squamous cell carcinoma (HNSCC) are highly invasive and proliferative and exhibit a poor five-year survival rate, mainly due to poor understanding of HNSCC pathogenesis mechanisms, preventing efficient treatment. Ubiquitin‑specific peptidase 22 (USP22) is an important component of cell cycle regulation, as it indirectly affects chromatin structure via histone ubiquitination and regulates activation of gene transcription. In previous studies, silencing of USP22 significantly inhibited tumor cell proliferation. To investigate the expression levels and the role of USP22 in the carcinogenesis of human pharyngeal squamous cell carcinoma, pharyngeal squamous cell carcinoma and adjacent normal tissue samples were collected from four patients. Six pharyngeal squamous cell carcinoma cell lines (SAS, CAL-33, FaDu, HSC-4, UTSCC-5 and UTSCC-8) were also included in this study. The USP22 mRNA and protein expression levels in the patient and cell‑line samples were evaluated using quantitative polymerase chain reaction and western blotting analyses. Subsequently, stable USP22 gene silencing in cells was achieved using lentiviral-delivered small interfering RNA (siRNA), and an MTT assay was used to evaluate tumor cell proliferation. Expression levels of cell cycle-associated proteins following USP22 knockdown were assessed using western blot analysis. The results revealed that USP22 was upregulated in pharyngeal squamous cell carcinoma. USP22 knockdown, using lentivirus‑delivered siRNA, increased the expression levels of cell cycle proteins P21 and P27, but reduced the levels of phosphorylated retinoblastoma protein, resulting in the inhibition of FaDu cell growth and proliferation. In conclusion, USP22 is involved in the carcinogenesis of human pharyngeal squamous cell carcinoma through regulating tumor cell growth and proliferation.

View Figures

View References

1	Parkin DM, Bray F, Ferlay J and Pisani P: Global cancer statistics, 2002. CA Cancer J Clin. 55:74–108. 2005. View Article : Google Scholar
2	Hunter KD, Parkinson EK and Harrison PR: Profiling early head and neck cancer. Nat Rev Cancer. 5:127–135. 2005. View Article : Google Scholar : PubMed/NCBI
3	Pai SI and Westra WH: Molecular pathology of head and neck cancer: implications for diagnosis, prognosis, and treatment. Annu Rev Pathol. 4:49–70. 2009. View Article : Google Scholar : PubMed/NCBI
4	Stadler ME, Patel MR, Couch ME and Hayes DN: Molecular biology of head and neck cancer: risks and pathways. Hematol Oncol Clin North Am. 22:1099–1124. 2008. View Article : Google Scholar : PubMed/NCBI
5	Tuyns AJ: Aetiology of head and neck cancer: tobacco, alcohol and diet. Adv Otorhinolaryngol. 46:98–106. 1991.PubMed/NCBI
6	D’Souza G and Dempsey A: The role of HPV in head and neck cancer and review of the HPV vaccine. Prev Med. 53(Suppl 1): S5–S11. 2011.PubMed/NCBI
7	Goh HK, Ng YH and Teo DT: Minimally invasive surgery for head and neck cancer. Lancet Oncol. 11:281–286. 2010. View Article : Google Scholar : PubMed/NCBI
8	Le Tourneau C, Faivre S and Siu LL: Molecular targeted therapy of head and neck cancer: review and clinical development challenges. Eur J Cancer. 43:2457–2466. 2007.PubMed/NCBI
9	Chisholm E, Bapat U, Chisholm C, Alusi G and Vassaux G: Gene therapy in head and neck cancer: a review. Postgrad Med J. 83:731–737. 2007. View Article : Google Scholar : PubMed/NCBI
10	De Costa AM and Young MR: Immunotherapy for head and neck cancer: advances and deficiencies. Anticancer Drugs. 22:674–681. 2011.PubMed/NCBI
11	Brennan P and Boffetta P: Mechanistic considerations in the molecular epidemiology of head and neck cancer. IARC Sci Publ; pp. 393–414. 2004
12	Leong PL, Xi S, Drenning SD, et al: Differential function of STAT5 isoforms in head and neck cancer growth control. Oncogene. 21:2846–2853. 2002. View Article : Google Scholar : PubMed/NCBI
13	Fan GK, Fujieda S, Sunaga H, et al: Expression of protein p27 is associated with progression and prognosis in laryngeal cancer. Laryngoscope. 109:815–820. 1999. View Article : Google Scholar : PubMed/NCBI
14	Yuen PW, Man M, Lam KY and Kwong YL: Clinicopathological significance of p16 gene expression in the surgical treatment of head and neck squamous cell carcinomas. J Clin Pathol. 55:58–60. 2002. View Article : Google Scholar : PubMed/NCBI
15	Pavelić K, Krizanac S, Cacev T, et al: Aberration of FHIT gene is associated with increased tumor proliferation and decreased apoptosis-clinical evidence in lung and head and neck carcinomas. Mol Med. 7:442–453. 2001.PubMed/NCBI
16	Lee HJ, Kim MS, Shin JM, et al: The expression patterns of deubiquitinating enzymes, USP22 and Usp22. Gene Expr Patterns. 6:277–284. 2006. View Article : Google Scholar : PubMed/NCBI
17	Zhang XY, Varthi M, Sykes SM, et al: The putative cancer stem cell marker USP22 is a subunit of the human SAGA complex required for activated transcription and cell-cycle progression. Mol Cell. 29:102–111. 2008. View Article : Google Scholar : PubMed/NCBI
18	Glinsky GV, Berezovska O and Glinskii AB: Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer. J Clin Invest. 115:1503–1521. 2005. View Article : Google Scholar
19	Ning J, Zhang J, Liu W, Lang Y, Xue Y and Xu S: Overexpression of ubiquitin-specific protease 22 predicts poor survival in patients with early-stage non-small cell lung cancer. Eur J Histochem. 56:e462012. View Article : Google Scholar : PubMed/NCBI
20	Li ZH, Yu Y, Du C, et al: RNA interference-mediated USP22 gene silencing promotes human brain glioma apoptosis and induces cell cycle arrest. Oncol Lett. 5:1290–1294. 2013.PubMed/NCBI
21	Ling SB, Sun DG, Tang B, et al: Knock-down of USP22 by small interfering RNA interference inhibits HepG2 cell proliferation and induces cell cycle arrest. Cell Mol Biol (Noisy-le-grand). 58(Suppl): OL1803–OL1808. 2012.PubMed/NCBI
22	Henschel A, Buchholz F and Habermann B: DEQOR: a web-based tool for the design and quality control of siRNAs. Nucleic Acids Res. 32:W113–W120. 2004. View Article : Google Scholar : PubMed/NCBI
23	Arens C: Transoral treatment strategies for head and neck tumors. GMS Curr Top Otorhinolaryngol Head Neck Surg. 11:Doc052012.PubMed/NCBI
24	Zhao Y, Lang G, Ito S, et al: A TFTC/STAGA module mediates histone H2A and H2B deubiquitination, coactivates nuclear receptors, and counteracts heterochromatin silencing. Mol Cell. 29:92–101. 2008. View Article : Google Scholar
25	Ovaa H, Kessler BM, Rolén U, et al: Activity-based ubiquitin-specific protease (USP) profiling of virus-infected and malignant human cells. Proc Natl Acad Sci USA. 101:2253–2258. 2004. View Article : Google Scholar : PubMed/NCBI
26	Atanassov BS, Evrard YA, Multani AS, et al: Gcn5 and SAGA regulate shelterin protein turnover and telomere maintenance. Mol Cell. 35:352–364. 2009. View Article : Google Scholar : PubMed/NCBI
27	Smith S: The SAGA continues... to the end. Mol Cell. 35:256–258. 2009. View Article : Google Scholar
28	Glinsky GV: Genomic models of metastatic cancer: functional analysis of death-from-cancer signature genes reveals aneuploid, anoikis-resistant, metastasis-enabling phenotype with altered cell cycle control and activated Polycomb Group (PcG) protein chromatin silencing pathway. Cell Cycle. 5:1208–1216. 2006.
29	Glinsky GV: Death-from-cancer signatures and stem cell contribution to metastatic cancer. Cell Cycle. 4:1171–1175. 2005. View Article : Google Scholar : PubMed/NCBI
30	Liang J, Zhang X, Xie S, et al: Ubiquitin-specific protease 22: a novel molecular biomarker in glioma prognosis and therapeutics. Med Oncol. 31:8992014. View Article : Google Scholar : PubMed/NCBI
31	Chipumuro E and Henriksen MA: The ubiquitin hydrolase USP22 contributes to 3′-end processing of JAK-STAT-inducible genes. FASEB J. 26:842–854. 2012.PubMed/NCBI
32	Schrecengost RS, Dean JL, Goodwin JF, et al: USP22 regulates oncogenic signaling pathways to drive lethal cancer progression. Cancer Res. 74:272–286. 2014. View Article : Google Scholar : PubMed/NCBI